- Home
- PHGE vs AEHL Comparison
PHGE vs AEHL Comparison
Compare PHGE & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- AEHL
- Stock Information
- Founded
- PHGE 2015
- AEHL 1993
- Country
- PHGE Israel
- AEHL China
- Employees
- PHGE N/A
- AEHL N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- AEHL Building Materials
- Sector
- PHGE Health Care
- AEHL Industrials
- Exchange
- PHGE Nasdaq
- AEHL Nasdaq
- Market Cap
- PHGE 15.5M
- AEHL 17.3M
- IPO Year
- PHGE N/A
- AEHL 2007
- Fundamental
- Price
- PHGE $0.58
- AEHL $2.96
- Analyst Decision
- PHGE Strong Buy
- AEHL
- Analyst Count
- PHGE 1
- AEHL 0
- Target Price
- PHGE $15.00
- AEHL N/A
- AVG Volume (30 Days)
- PHGE 397.5K
- AEHL 193.6K
- Earning Date
- PHGE 11-13-2025
- AEHL 09-25-2025
- Dividend Yield
- PHGE N/A
- AEHL N/A
- EPS Growth
- PHGE N/A
- AEHL N/A
- EPS
- PHGE N/A
- AEHL N/A
- Revenue
- PHGE N/A
- AEHL $98,773,000.00
- Revenue This Year
- PHGE N/A
- AEHL N/A
- Revenue Next Year
- PHGE N/A
- AEHL N/A
- P/E Ratio
- PHGE N/A
- AEHL N/A
- Revenue Growth
- PHGE N/A
- AEHL 36.99
- 52 Week Low
- PHGE $0.34
- AEHL $1.79
- 52 Week High
- PHGE $1.16
- AEHL $20.25
- Technical
- Relative Strength Index (RSI)
- PHGE 53.87
- AEHL 42.57
- Support Level
- PHGE $0.55
- AEHL $2.76
- Resistance Level
- PHGE $0.63
- AEHL $3.14
- Average True Range (ATR)
- PHGE 0.05
- AEHL 0.42
- MACD
- PHGE -0.00
- AEHL -0.11
- Stochastic Oscillator
- PHGE 35.85
- AEHL 12.40
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.